中国临床药理学杂志2018，Vol.34Issue(10)：1144-1146,1150,4.DOI:10.13699/j.cnki.1001-6821.2018.10.004
非小细胞肺癌中表皮生长因子受体(EGFR)复合突变与EGFR酪氨酸激酶抑制剂治疗敏感性研究
Correlation between epidermal growth factor receptor (EGFR) mutations and EGFR-tyrosine inhibitors therapy sensibility in non-small cell lung cancer
摘要
Abstract
Objective To investigate the relationship between epidermal growth factor receptor (EGFR) mutation and the clinical sensitivity of EGFR tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer,and to provide basis for the EGFR-TKI therapy in patients with EGFR mutation of non-small cell lung cancer.Methods The clinical data of 95 patients with EGFR mutation of non-small cell lung cancer treated with EGFR-TKI were retrospectively analyzed.Patients were orally given EGFR-TKI until the disease progressed or was unable to tolerate the serious adverse drug reactions and surgically treated.The type of EGFR gene mutation,the postoperative survival of patients and the therapeutic effect of different types of EGFR-TKI were compared.Results In 95 patients with EGFR mutation of non-small cell lung cancer,EGFR-TKI sensitive mutations in exon 21 and exon 19 were 31.58％ and 36.84％,and EGFR recombination mutation rate was 18.94％.The disease control rates of exon 19 deletion mutation and exon 21 L858R point mutation were 83.87％ and 75.00％,while the control rate of the compound mutation after TKI treatment was 100.00％.Conclusion Most EGFR-TKI-sensitive EGFR mutations are attributed to EGFR-TKI after combination with atypical EGFR mutations,and have a high disease control rate.关键词
上皮生长因子受体/非小细胞肺癌/酪氨酸激酶抑制药Key words
epidermal growth factor receptor/non-small cell lung cancer/tyrosine kinase inhibitor分类
医药卫生引用本文复制引用
黄珊,刘迪..非小细胞肺癌中表皮生长因子受体(EGFR)复合突变与EGFR酪氨酸激酶抑制剂治疗敏感性研究[J].中国临床药理学杂志,2018,34(10):1144-1146,1150,4.
